Compare IDEXX Laboratories, Inc. (IDXX) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs ThredUp Inc — how do they compare? IDEXX Laboratories, Inc. trades at $567.52 (market cap $44.95B), while ThredUp Inc trades at $3.2 (market cap $405.82M). The key difference: IDEXX Laboratories, Inc. is far larger — about 110.8× ThredUp Inc's market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, ThredUp Inc nearer its low. Which is the better fit depends on your goals.
| IDXX | TDUP | |
|---|---|---|
Market Cap | $44.95B | $405.82M |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $12.08 |
52-Week Low | $526.44 | $3.08 |
Enterprise Value | $45.85B | $404.00M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $566.93, down 3.36% on the day, with a neutral technical signal and strong support near $565. The company reported robust Q2 2026 earnings, beating EPS estimates with $4.27 versus $3.94 expected, and raised full-year EPS guidance to $14.69–14.94. Revenue grew 10% year-over-year, driven by companion animal diagnostics, while profitability remains high with a net margin of 25.03% in 2025. Analyst consensus is bullish with a $683.33 price target, though valuation multiples like P/E of 40.1 suggest a premium.
Outlook is positive due to consistent earnings beats, international expansion, and innovation in veterinary diagnostics, but risks include elevated valuation sensitivity, competitive pressures, and reliance on pet healthcare spending. The stock offers growth potential if execution continues, yet investors should weigh high multiples against sustained profitability trends.
ThredUp (TDUP) trades at $3.17, up 0.96% on the day, but remains under pressure after a significant Q2 2026 earnings miss and lowered full-year revenue guidance. The stock's technical picture is bearish, while fundamentals show improving revenue growth but persistent losses. Recent news highlights an ongoing securities investigation related to the guidance revision, contributing to negative sentiment.
The outlook is cautious. While analyst consensus is technically 'Buy' (57% of ratings), recent operational setbacks and the stock's sharp decline post-earnings suggest significant near-term risk. The primary opportunity lies in the company's high gross margins and active buyer growth, but profitability remains elusive and investor confidence is fragile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
